Abstract：Objective To study the effect of cyclooxygenase -2 selective inhibitor celecoxib on the expression of major vault protein ( MVP) in the brain of rats with status epilepticus and its possible roles in the treatment of refractory epilepsy. Methods Sixty adult male Sprague-Dawley rats were randomly assigned to blank control (n=16), epilepsy model (n=22) and celecoxib treatment groups (n=22). After the status epilepticus was induced in rats by injecting lithium and pilocarpine, each group had 16 rats enrolled as subjects. Immunohistochemical method and Western blot method were used to detect the expression of MVP in the frontal cortex and hippocampus. Results The expression of MVP was significantly higher in the epilepsy model group than in the control group (PPConclusions Celecoxib could decrease the expression of MVP in brain tissue of rats with status epilepticus, suggesting that it is promising for the treatment of intractable epilepsy.
SONG Ting-Ting,LI Dan,HUANG Shao-Ping et al. Effects of cyclooxygenase-2 selective inhibitor celecoxib on the expression of major vault protein in rats with status epilepticus[J]. CJCP, 2016, 18(5): 440-445.
Vezzani A, Aronica E, Mazarati A, et al. Epilepsy and brain inflammation[J]. Exp Neurol, 2013, 244: 11-21.
[3]
Schlichtiger J, Pekcec A, Bartmann H, et al. Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy[J]. Br J Pharmacol, 2010, 160(5): 1062-1071.
Sun Q, Li Y. The inhibitory effect of pseudolaric acid B on gastric cancer and multidrug resistance via Cox-2/PKC-α/P-gp pathway[J]. PLoS One, 2014, 9(9): e107830.
Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure[J]. Electroencephalogr Clin Neurophysiol, 1972, 32(3): 281-294.
[8]
Liu B, Wang T, Wang L, et al. Up-regulation of major vault protein in the frontal cortex of patients with intractable frontal lobe epilepsy[J]. J Neurol Sci, 2011, 308(1-2): 88-93.
[9]
Balan S, Radhab SK, Sathyan S, et al. Major vault protein (MVP) gene polymorphisms and drug resistance in mesial temporal lobe epilepsy with hippocampal sclerosis[J]. Gene, 2013, 526(2): 449-453.
[10]
Kedersha NL, Rome LH. Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA[J]. J Cell Biol, 1986, 103(3): 699-709.
[11]
Gotovdorj T, Lee E, Lim Y, et al. 2,3,7,8-Tetrachlorodibenzop-dioxin induced cell-specific drug transporters with acquired cisplatin resistance in cisplatin sensitive cancer cells[J]. J Korean Med Sci, 2014, 29(9): 1188-1198.
Rojas A, Jiang J, Ganesh T, et al. Cyclooxygenase-2 in epilepsy[J]. Epilepsia, 2014, 55(1): 17-25.
[14]
Auvin S, Shin D, Mazarati A, et al. Inflammation induced by LPS enhances epileptogenesis in immature rat and may be partially reversed by IL1RA[J]. Epilepsia, 2010, 51 Suppl 3: 34-38.
[15]
van Vliet EA, Zibell GA, Schlichtiger J, et al. COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats[J]. Neuropharmacology, 2010, 58(2): 404-412.
[16]
Citraro R, Leo A, Marra R, et al. Antiepileptogenic effects of the selective COX-2 inhibitor etoricoxib, on the development of spontaneous absence seizures in WAG/Rij rats[J]. Brain Res Bull, 2015, 113: 1-7.
[17]
Annamaria V. Anti-inflammatory drugs in epilepsy: does it impact epileptogenesis? [J]. Expert Opin Drug Saf, 2015, 14(4): 583-592.
Polascheck N, Bankstahl M, Löscher W. The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy[J]. Exp Neurol, 2010, 224(1): 219-233.
